Proteonomix, Inc (PROT.OB) is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives with an initial focus on diabetes and cardiac diseases.
Many of the currently incurable diseases associated with aging are caused by the degeneration of specific cell types in the body. These diseases include, but are not limited to, cancer, heart disease, diabetes, and autoimmune conditions. Stem cell therapy provides much promise for the treatment of diseases previously regarded as incurable.
Through operating subsidiary, National Stem Cell, Proteonomix has developed a catalog of intellectual properties and patent applications. These technologies are designed to work together in a synergistic fashion.
Through National Stem Cell, Proteonomix has developed a patent-pending container device for cryopreservation of stem cells (the process where cells are preserved by cooling to low sub-zero temperatures) that the Company believes will provide significant improvements in viable cell recovery and contaminant protection, both in freezing and thawing stem cells, than is found with cryostorage containers currently in use.
Multiple cosmetic products have been developed through subsidiary Proteoderm. The products are based on patents describing Secreted Matrix TM technology. These products are currently in production and are available now.
Laboratory services are provided by wholly owned, accredited and operating reproductive cell/tissue banking service (sperm, ova, ovarian tissue, testicular tissue and embryos). It is anticipated that Proteonomix’s laboratory services will provide advanced technologies and procedures for the collection, laboratory testing, bio-genetic typing, processing and cryogenic storage of stem cells from both umbilical cord and peripheral blood.
Umbilical cord blood stem cells and reproductive cells are processed and banked for both allogeneic (transfer from one person to another) and autologous (derived from and used by the same individual) therapeutic transplantation for a variety of medical disorders, including leukemia and lymphoma with stem cells and infertility with sperm cells. Proteonomix has developed and implemented a unique, effective and comprehensive strategy for the marketing of their services and products on a national and international scale for applications in stem cell therapeutics together with cell-tissue laboratory services.
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) reports that its partner, Green Cross Corporation has received marketing and manufacturing approval from KFDA (Korean Food & Drug Administration) for intravenous (i.v.) peramivir to treat patients with influenza A & B viruses, including pandemic H1N1 and avian influenza. Green Cross Corp. intends to launch peramivir under the commercial name PeramiFlu in South Korea.
�We congratulate Green Cross on this achievement,� said Jon P. Stonehouse, President and Chief Executive Officer of BioCryst. �We are pleased that intravenous peramivir is now approved in Korea and represents the second country this year to make this important treatment option available for patients suffering from seasonal influenza. BioCryst continues to focus on completing the U.S. development of i.v. peramivir as a potential treatment for hospitalized patients with seasonal influenza.�
Green Cross Corp. received the indication of single dose administration of 300 mg i.v. peramivir for treatment of adults with influenza A & B infection. In November 2009, after review through the Central Pharmaceutical Affairs Council, peramivir received approval for limited use in Korea in emergency cases. Approximately 50 individuals were treated under emergency use in Korea.
In June 2006, BioCryst Pharmaceuticals and Green Cross Corporation entered into an agreement that granted Green Cross Corp. the right to develop and commercialize peramivir in South Korea. As part of the agreement, Green Cross Corp. paid to BioCryst a one-time license fee. BioCryst will receive a double-digit royalty on all commercial sales, with the royalty rate being higher for non-commercial sales made to the S. Korean Government.
CryoLife, Inc., (NYSE:CRY) an implantable biological medical device and cardiovascular tissue processing company, has received 510(k) clearance from the Food and Drug Administration (FDA) for a five-year shelf-life on its CryoPatch SG pulmonary human cardiac patch processed with the Company’s proprietary SynerGraft technology. CryoLife’s SynerGraft technology is designed to remove allogeneic donor cells and cellular remnants from tissue without compromising the integrity of the underlying collagen matrix.
“This shelf-life extension allows us to make this advanced technology available to more patients,” said Steven G. Anderson, CryoLife’s president and chief executive officer. “Further, the extended five-year shelf life will simplify the purchasing decisions and tissue inventory management for hospitals.”
CryoPatch SG is indicated for the repair or reconstruction of the right ventricular outflow tract (RVOT), which is a surgery commonly performed in children with congenital heart defects, such as Tetralogy of Fallot, Truncus Arteriosus, and Pulmonary Atresia. CryoPatch SG is distributed in three anatomic configurations: pulmonary hemi-artery, pulmonary trunk, and pulmonary branch.
Implantation of the CryoPatch SG reduces the risk for induction of HLA class I and class II alloantibodies, based on Panel Reactive Antibody (PRA) measured at up to one year, compared to standard processed pulmonary cardiac tissues. Data have not been provided to evaluate the effect of reduced alloantibodies on the long-term durability, or long-term resistance to rejection by the patient, of the CryoPatch SG.
Avoiding elevated PRA is important for patients receiving CryoPatch SG as some may ultimately require a heart transplant. While the link between immune response and allograft tissue performance is still being debated, there is evidence that an elevated PRA can pose a significant risk to future organ transplant patients.
No comments :
Post a Comment